Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Victoria, Australia from 2013 to 2018

Suzanne Nielsen1, Rose Crossin1,2, Melissa Middleton1, Tina Lam1, James Wilson2, Debbie Scott1,2, Catherine Martin3, Karen Smith1,4,5,6, & Dan Lubman1,2

Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Frankston, Victoria, Australia; 1 Turning Point, Eastern Health and Eastern Health Clinical School, Monash University, Richmond, Victoria, Australia; 2 Biostatistical Unit, Public Health and Preventative Medicine, Monash University, Melbourne, Victoria, Australia; 3 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; 4 Ambulance Victoria, Doncaster, Victoria, Australia; 5 and Department of Community Emergency Health and Paramedic Practice, Monash University, Frankston, Victoria, Australia

ABSTRACT

Background and aims Despite increases in opioid prescribing and related morbidity and mortality, few studies have comprehensively documented harms across opioid types. We examined a population-wide indicator of extramedical pharmaceutical opioid-related harm to determine if the supply-adjusted rates of ambulance presentations, the severity of presentations or other attendance characteristics differed by opioid type. Design Retrospective observational study of coded ambulance patient care records related to extramedical pharmaceutical opioid use, January 2013 to September 2018. Setting Australia Cases Primary analyses used Victorian data (n = 9823), with available data from other Australian jurisdictions (n = 4338) used to determine generalizability. Measurements We calculated supply-adjusted rates of attendances using Poisson regression, and used multinomial logistic regression to compare demographic, presentation severity, mental health, substance use and other characteristics of attendances associated with seven pharmaceutical opioids. Findings In Victoria, the highest rates of attendance [per 100 000 oral morphine equivalent mg (OME)] were for codeine (0.273/100 000) and oxycodone (0.113/100 000). The lowest rates were for fentanyl (0.019/100 000) and tapentadol (0.005/100 000). Oxycodone–naloxone rates (0.031/100 000) were lower than for oxycodone as a single ingredient (0.113/100 000). Fentanyl-related attendances were associated with the most severe characteristics, most likely to be an accidental overdose, most likely to have naloxone administered and least likely to be transferred to hospital. In contrast, codeine-related attendances were more likely to involve suicidal thoughts/behaviours, younger females and be transported to hospital. Supply-adjusted attendance rates for individual opioids were stable over time. Victorian states were broadly consistent with non-Victorian states. Conclusions In Australia, rates and characteristics of opioid-related harm vary by opioid type. Supply-adjusted ambulance attendance rates appear to be both stable over time and unaffected by large changes in supply.

Keywords Ambulance, extramedical use, opioid analgesic, overdose, oxycodone, tapentadol.

INTRODUCTION

The increasing use of pharmaceutical opioids is well documented in many high-income countries [1]. In the United States, 35% of all opioid-related deaths are attributed to pharmaceutical opioids, and the rate of pharmaceutical-opioid related deaths has risen more than threefold from 1.4/100 000 in 1999 to 5.2/100 000 in 2017 [2]. In Australia, mortality for all-opioids has almost doubled in the past decade from 3.8 to 6.6 deaths per 100 000, with 1045 opioid-related deaths in 2016, 70% of which were pharmaceutical opioid-related [3,4]. Pharmaceuticals opioids are often considered as a homogeneous group when their harms are reported. Most
opioids exert their analgesic effect through the mu-opioid receptor; however, opioids can differ in important ways, such as their potency as analgesics and pharmacokinetics [5]. One study examining rates of severe adverse events (SAEs) found a strong positive association with potency and SAEs [6]. Fentanyl is considered a high-potency opioid with rapid onset, high lipophilicity and short duration of action (30 minutes). Oxycodone and morphine are examples of medium-potency opioids with a slower onset (30–60 minutes) and longer duration of action (3–4 hours) [7,8]. Codeine, tramadol and tapentadol are examples of lower-potency opioids [5]. Tramadol and tapentadol are sometimes called ‘atypical opioids’, as their mu-opioid effects are combined with serotonin and/or noradrenaline re-uptake pharmacological actions [9–11].

Abuse liability also differs between opioids. For example, oxycodone has a consistently robust abuse liability profile [12]. In contrast, codeine is relatively less reinforcing [13]. Contextual factors such as cost and availability also affect propensity for extramedical use and harms; therefore, studies in real-world settings are important [14].

Sentinel surveillance studies can identify harms associated with different opioids (e.g. the National Illicit Drug Reporting System [15]), although these studies often target specific subpopulations of interest rather than the general population and are less useful for newer or less commonly used opioids. Mortality data can also provide an indication of relative harms; however, reporting can have up to a 3-year delay, and deaths are a relatively lower-frequency event. Finally, reporting systems that capture spontaneous adverse events are important, although these systems are known to be subject to under-reporting and selective reporting bias [16].

Ambulance attendance data have the potential to provide population-level data and address many of these limitations. Ambulance services are near-universal in Australia, with state-wide responsibility for service delivery. Paramedics are often the first or only health professionals that directly observe the scene (e.g. medicine packets, bystander accounts), providing unique and valuable information. A well-established programme of research (the National Ambulance Surveillance System) has developed a validated method of coding paramedic clinical records associated with substance use-related ambulance attendances [17].

The aim of this study was to compare the rates and characteristics of pharmaceutical opioid-related ambulance attendances.

Specifically, we questioned:
1. Do the supply-adjusted rates of ambulance presentations differ by opioid type?
2. Does the severity of presentation or other attendance characteristics differ by opioid type?

**METHODS**

The study’s research questions, methods and analysis plan were published a priori [17], and reported in compliance with The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement (Supporting information, Table S1).

**Study design and setting**

We used ambulance attendance data from January 2013 to September 2018. The primary analysis represent data from the state of Victoria, which comprises approximately 26% of the Australian population (5.7 million residents in 2013 and 6.5 million in 2018) [18]. To determine generalizability, we compared our continuous data set of Victorian pharmaceutical opioid attendances with data from ‘snapshot months’ from the other jurisdictions [Queensland, New South Wales (NSW), Australian Capital Territory (ACT), Northern Territory and Tasmania]. Snapshot data were available for the months March, June, September and December for 2015–17 [17]. Data for Western Australia and South Australia are not yet available for analysis.

**Ambulance attendance data**

Data are from the previously described [19,20] National Ambulance Surveillance System [21]. Briefly, electronic patient care records (ePCR), computer-aided dispatch and other clinical details are provided to Turning Point for data cleaning, validation and coding by specialist research assistants using a systematic and validated coding method [17].

Cases where the recent extramedical (i.e. over- or inappropriate) use of a pharmaceutical drug is assessed to have significantly contributed to the reason for the ambulance attendance are identified from the ePCR. Substance involvement and other associated factors including clinical presentation, mental health symptoms and self-harm are coded.

For this study, all ambulance attendances involving extramedical use of buprenorphine, codeine, fentanyl, oxycodone, oxycodone–naloxone, morphine, pethidine, tramadol and tapentadol were included. Seven of these are routinely coded. Codeine is coded under four different variables (codeine, codeine + aspirin, codeine + ibuprofen, codeine + paracetamol), so a single aggregated variable was created. Tapentadol is coded as an ‘other opioid’. Therefore, to identify tapentadol-related attendances, ‘other opioid’ attendances were searched using keywords (see Supporting information, Table S2 for the comprehensive search strategy).

We excluded attendances related to opioid agonist treatment (for opioid dependence), as these represent a
specific clinical population and indication. Further, we excluded attendances with individuals aged < 12 years (n = 32), due to unclear intention of use in children [22,23]. Deaths were not excluded, but are not quantified due to data-capture inconsistencies.

Sales data

To calculate a supply-adjusted rate of attendances, we used sales data (IQVIA third-party access program). We calculated the total amount of each opioid supplied per month in milligrams (mg), converted to oral morphine equivalents (OME) [24]. OME is a widely used measure to quantify population-level opioid use, with advantages over defined daily doses [25].

Variables

The primary independent variable was opioid type. We assessed trends within each opioid where a single opioid was involved, as well as a ‘multiple opioid’ category (i.e. more than one of the opioids examined as part of the study contributed to the attendance). Outcome variables and covariates describe the context and characteristics of the attendances (Supporting information, Table S3). These include the Glasgow Coma Scale (GCS) as a measure of medical severity; respiration rate; transport to hospital; naloxone administration; naloxone response; age; sex; socio-economic status based on residential postcode [26]; concurrent alcohol use, illicit drug use excluding heroin, heroin use and non-opioid pharmaceutical involvement; comorbid mental health, suicidal thoughts or behaviours or non-suicidal self-injury; and accidental overdose, unknown intent overdose or past psychiatric history.

Statistical analysis

Analyses were planned a priori [17].

Rates of attendances per 100 000 mg of opioid supplied

Attendances were aggregated into 3-monthly periods. Regression (Poisson) models were fitted for each opioid. Temporal variations were explored and were apparent only for codeine, so were not adjusted for the final models. Estimates are presented as incidence rate ratios (IRRs) and represent the estimated rate ratio associated with a 1-year increase. Monthly rates were calculated for Victoria, and compared with other states for corresponding time-periods as a sensitivity analysis.

Characteristics of attendances

Multinomial logistic regression was used to analyse characteristics of opioid-related attendances by opioid type. Each attendance characteristic was regressed separately with opioid type as the dependent variable; morphine, a mid-potency opioid considered the standard reference for calculating opioid doses, was the reference category.

When considering severity of presentations (measured with GCS), the model was adjusted for age, sex (as male/female only), concurrent alcohol use, concurrent illicit drug use (excluding heroin), concurrent heroin use and concurrent non-opioid pharmaceutical use. All other models were adjusted for age, sex and other substance use (as an aggregated variable of concurrent alcohol use, illicit drug use, heroin and non-opioid pharmaceutical misuse). Deaths were not excluded, but are not separately reported due to small cell sizes. State location (Victoria or ‘other jurisdictions’) was assessed as an effect modifier when case numbers allowed.

All analyses were undertaken in Stata (StataCorp 2013), with P-values less than 0.05 considered significant, with no correction for multiple testing [27].

Missing data

Missing data were minimal (< 5%, Supporting information, Table S4). For data missing due to industrial action, we ran planned sensitivity analysis using imputed data.

Changes from planned analyses

Due to low numbers of attendances with buprenorphine and pethidine (≤ 5 in total over the study period), we were unable to explore presentation characteristics or calculate quarterly rates, although these opioids contributed to the multiple opioid category when involved in other attendances.

Ethics committee approval

This project was approved by the Eastern Health Human Research Ethics Committee (E122–0809). Cells with n < 5 are not reported to preserve confidentiality, per conditions of approval.

RESULTS

We identified 9823 opioid-related ambulance attendances in Victoria across the almost 6-year study period, with a further 4338 captured in NSW, ACT, Northern Territory, Queensland and Tasmania during the relevant ‘snapshot’ months. Codeine and oxycodone were the most prevalent opioids, representing 67% of cases combined. Overall, 9.7% of cases involved multiple opioids.

Aim 1—supply-adjusted trends

The supply-adjusted ambulance attendances rate was highest for codeine [0.273/100 000 mg OME, 95% confidence interval (CI) = 0.261–0.285] and lowest for
tapeentadol (0.005/100,000 mg OME, 95% CI = 0.003–0.007) (Table 1, Fig. 1). Supporting information, Fig. S1 depicts the raw attendance and supply data used to calculate the supply-adjusted rates.

The Poisson regression estimates show that the mean monthly attendance rates for Victoria were stable over time (Table 1). The mean monthly supply-adjusted rates for each year (Table 2) were generally consistent with the Poisson regression findings, with the exception of oxycodone. The supply-adjusted oxycodone rate was stable from 2014 to 2017. However, the rates in the first and last years examined fall outside the 95% CI for the overall study period, indicating an increase in supply-adjusted oxycodone attendance rates over that time.

Results using multiply imputed data were consistent with findings from the primary analysis (Supporting information, Table S5). Results for quarterly snapshot months from states outside Victoria were broadly consistent with patterns observed with the complete Victorian data set for the Poisson regression, with larger confidence intervals representing the greater uncertainty involved in using snapshot months with fewer cases (Supporting information, Table S6). However, the rates for fentanyl and morphine appeared higher outside Victoria, with the most noticeable difference seen for morphine, with a significantly higher estimated monthly rate.

**Aim 2—characteristics of attendances**

Attendance characteristics are presented for each opioid in Supporting information, Table S7, and relative to morphine in Table 3. We report differences from the reference opioid (morphine) below.

As case severity (measured with GCS) increased, fentanyl was more likely to be involved as a sole opioid. The opposite association was seen for oxycodone, oxycodone–naloxone, codeine, tramadol and multiple opioid attendances. The largest change occurred for oxycodone–naloxone, in which attendances with minor–no impairment, compared to non-responsive attendances, were more likely to be oxycodone–naloxone-related rather than morphine-related [odds ratio (OR) = 9.55, 95% CI = 4.03–...
rates of supply-adjusted pharmaceutical opioid-related ambulance attendances (Victoria only). [Colour figure can be viewed at wileyonlinelibrary.com]}

was less likely to be reported. Similarly, extramedical non-opioid pharmaceutical use was more likely with opioids other than morphine (excluding fentanyl), with this being most likely with tapentadol (OR = 3.66; 95% CI = 1.42–9.44; P = 0.007).

Mental health symptoms were less likely to be reported with fentanyl (OR = 0.39, 95% CI = 0.22–0.70; P = 0.001) and more likely with codeine (OR = 1.42, 95% CI = 1.08–1.86; P = 0.011) and oxycodone–naloxone (OR = 1.42, 95% CI = 1.01–2.02, P = 0.046), compared to morphine-related attendances. Conversely, when compared to morphine, history of psychiatric issues was more likely with all opioids other than fentanyl.

Codeine-related attendances were more likely to involve comorbid suicidal ideation (OR = 4.46, 95% CI = 3.52–5.66; P < 0.001) and less likely to involve an accidental overdose compared with morphine-related attendances (OR = 0.38, 95% CI = 0.28–0.52; P < 0.001). Accidental overdose-related attendances were most commonly fentanyl-related (OR = 2.89, 95% CI = 1.97–4.24; P < 0.001). Unknown intent-related attendances were more commonly associated with fentanyl (OR = 1.73, 95% CI = 1.60–2.63; P = 0.010), codeine (OR = 1.43, 95% CI = 1.07–1.92; P = 0.016) and less likely for oxycodone–naloxone (OR = 0.62, 95% CI = 0.40–0.97; P = 0.038) when compared to morphine.

When comparing Victorian results to the remaining states, there were too few attendances for tapentadol, oxycodone–naloxone and fentanyl outside Victoria to enable a comparison of characteristics. The effect of most characteristics remained the same across the states. GCS, age, alcohol involvement, unknown intent and past psychiatric history were the only characteristics in which the magnitude of effect changed, but the direction did not (data not presented). Non-suicidal self-injury in codeine-related cases and naloxone response in oxycodone–naloxone-related cases become inconclusive outside Victoria. Overall,
| Opioid               | Mean monthly supply-adjusted rate (per 100 000 mg oral morphine equivalents)\(^a\) | Year | 2013 | 2014\(^b\) | 2015 | 2016 | 2017 | 2018\(^b\) |
|---------------------|---------------------------------------------------------------------------------|------|------|-----------|------|------|------|-----------|
| Codeine             |                                                                                 |      |      |           |      |      |      |           |
| Sole                | 0.256 (0.227–0.285)                                                             | 0.267 (0.224–0.309) | 0.278 (0.253–0.303) | 0.264 (0.221–0.308) | 0.291 (0.265–0.316) | 0.285 (0.255–0.315) | 0.291 (0.265–0.316) |
| Multiple            | 0.033 (0.024–0.042)                                                             | 0.030 (0.022–0.038) | 0.043 (0.033–0.052) | 0.033 (0.028–0.039) | 0.042 (0.032–0.053) | 0.058 (0.040–0.077) | 0.058 (0.040–0.077) |
| Fentanyl            |                                                                                 |      |      |           |      |      |      |           |
| Sole                | 0.014 (0.010–0.018)                                                             | 0.016 (0.007–0.026) | 0.020 (0.014–0.026) | 0.020 (0.015–0.025) | 0.023 (0.014–0.032) | 0.018 (0.009–0.027) | 0.018 (0.009–0.027) |
| Multiple            | 0.004 (0.001–0.006)                                                             | 0.004 (0.001–0.008) | 0.004 (0.001–0.008) | 0.005 (0.000–0.009) | 0.001 (–0.000–0.002) | 0.004 (0.001–0.008) | 0.004 (0.001–0.008) |
| Morphine            |                                                                                 |      |      |           |      |      |      |           |
| Sole                | 0.049 (0.040–0.057)                                                             | 0.040 (0.025–0.056) | 0.055 (0.041–0.062) | 0.051 (0.039–0.062) | 0.054 (0.039–0.068) | 0.052 (0.038–0.066) | 0.052 (0.038–0.066) |
| Multiple            | 0.009 (0.005–0.013)                                                             | 0.009 (0.003–0.016) | 0.013 (0.007–0.019) | 0.008 (0.004–0.012) | 0.015 (0.007–0.022) | 0.015 (0.005–0.024) | 0.015 (0.005–0.024) |
| Oxycodone           |                                                                                 |      |      |           |      |      |      |           |
| Sole                | 0.089 (0.080–0.099)                                                             | 0.103 (0.088–0.117) | 0.108 (0.100–0.117) | 0.113 (0.103–0.123) | 0.120 (0.109–0.131) | 0.152 (0.126–0.178) | 0.152 (0.126–0.178) |
| Multiple            | 0.020 (0.016–0.023)                                                             | 0.021 (0.018–0.025) | 0.031 (0.025–0.038) | 0.032 (0.026–0.039) | 0.038 (0.030–0.045) | 0.039 (0.029–0.050) | 0.039 (0.029–0.050) |
| Oxycodone–naloxone  |                                                                                 |      |      |           |      |      |      |           |
| Sole                | 0.036 (0.020–0.053)                                                             | 0.037 (0.028–0.042) | 0.035 (0.028–0.042) | 0.022 (0.015–0.028) | 0.025 (0.019–0.032) | 0.036 (0.022–0.050) | 0.036 (0.022–0.050) |
| Multiple            | 0.011 (0.004–0.018)                                                             | 0.014 (0.005–0.023) | 0.017 (0.011–0.022) | 0.018 (0.014–0.023) | 0.020 (0.016–0.024) | 0.016 (0.009–0.023) | 0.016 (0.009–0.023) |
| Tapentadol          |                                                                                 |      |      |           |      |      |      |           |
| Sole                | 0                                                                                | 0.004 (0.000–0.008) | 0.008 (0.002–0.013) | 0.009 (0.003–0.015) | 0.007 (0.003–0.012) | 0.007 (0.003–0.012) | 0.007 (0.003–0.012) |
| Multiple            | 0                                                                                | 0.005 (–0.000–0.010) | 0.003 (–0.000–0.006) | 0.002 (0.000–0.004) | 0.004 (0.001–0.007) | 0.004 (0.001–0.007) | 0.004 (0.001–0.007) |
| Tramadol            |                                                                                 |      |      |           |      |      |      |           |
| Sole                | 0.040 (0.030–0.050)                                                             | 0.040 (0.031–0.049) | 0.038 (0.030–0.046) | 0.047 (0.036–0.057) | 0.048 (0.035–0.061) | 0.060 (0.046–0.075) | 0.060 (0.046–0.075) |
| Multiple            | 0.013 (0.009–0.018)                                                             | 0.014 (0.008–0.019) | 0.016 (0.010–0.022) | 0.018 (0.013–0.023) | 0.014 (0.010–0.017) | 0.016 (0.012–0.021) | 0.016 (0.012–0.021) |
| Multiple Opioids    | 0.092 (0.082–0.103)                                                             | 0.099 (0.075–0.123) | 0.133 (0.105–0.160) | 0.121 (0.101–0.142) | 0.207 (0.052–0.363) | 0.156 (0.121–0.191) | 0.156 (0.121–0.191) |

\(^a\)95% Confidence interval presented in brackets; \(^b\)Estimates calculated using 9-months of the year, reflecting available data.
| Characteristic                      | Codeine | Fentanyl | Oxycodone | Oxycodone–naloxone |
|-----------------------------------|---------|----------|-----------|-------------------|
|                                   | n       | OR       | 95% CI    | OR                | 95% CI     |
| Glasgow Coma Scale                | 9665    |          |           |                   |
| Non-responsive                   | Ref     | Ref      | Ref       | Ref               | Ref       |
| Severe impairment                | 2.66    | 1.40–5.02| 0.83      | 0.40–1.72         | 1.41      | 0.76–2.63 |
| Moderate impairment              | 2.81    | 1.65–4.79| 0.56      | 0.29–1.06         | 1.84      | 1.11–3.06 |
| Minor-no impairment              | 4.53    | 3.12–6.59| 0.19      | 0.13–0.29         | 2.06      | 1.45–2.91 |
| Age (years)                      | 14 073  |          |           |                   |
| 12–34                            | Ref     | Ref      | Ref       | Ref               | Ref       |
| 35–54                            | 0.39    | 0.30–0.49| 0.79      | 0.65–1.14         | 0.60      | 0.47–0.77 |
| 55–65                            | 0.24    | 0.17–0.33| 0.49      | 0.29–0.83         | 0.40      | 0.29–0.55 |
| > 65                             | 0.15    | 0.11–0.22| 0.41      | 0.23–0.71         | 0.45      | 0.32–0.63 |
| Sex                              | 14 073  |          |           |                   |
| Male                             | Ref     | Ref      | Ref       | Ref               | Ref       |
| Female                           | 2.99    | 2.45–3.65| 0.79      | 0.57–1.10         | 2.10      | 1.71–2.56 |
| Respiration rate                 | 9467    |          |           |                   |
| < 6                              | Ref     | Ref      | Ref       | Ref               | Ref       |
| 6–12                             | 5.89    | 3.15–11.02| 0.36    | 0.21–0.61         | 1.72      | 1.06–2.77 |
| > 12                             | 13.08   | 7.20–23.76| 0.14    | 0.08–0.23         | 2.13      | 1.37–3.23 |
| Transport to hospital             | 14 073  |          |           |                   |
| F                    | 2.63    | 1.99–3.47| 0.50      | 0.35–0.72         | 1.20      | 0.92–1.56 |
| Naloxone administered            | 14 073  |          |           |                   |
| F                    | 0.12    | 0.08–0.17| 3.97      | 2.77–5.69         | 0.59      | 0.44–0.78 |
| Naloxone response \(^{bc}\)     | 557     | 1.11     | 0.41–3.03| 2.51              | 0.86–7.33 | 1.12      | 0.53–2.38 |
| SEIFA quintile \(^{c}\)          | 9412    |          |           |                   |
| 1 (greatest disadvantage)        | Ref     | Ref      | Ref       | Ref               | Ref       |
| 2                                | 0.92    | 0.70–1.20| 1.09      | 0.70–1.68         | 0.98      | 0.75–1.19 |
| 3                                | 2.91    | 2.00–4.24| 1.47      | 0.81–2.64         | 2.62      | 1.79–2.94 |
| 4                                | 1.39    | 1.03–1.87| 1.08      | 0.66–1.76         | 1.43      | 1.06–1.93 |
| 5 (least disadvantage)           | 2.03    | 1.46–2.83| 1.54      | 0.92–2.57         | 1.49      | 1.07–2.09 |
| Alcohol involvement \(^{c}\)     | 14 073  |          |           |                   |
| Not stated                       | Ref     | Ref      | Ref       | Ref               | Ref       |
| Alcohol involved, no intoxication| 1.45    | 1.00–2.09| 1.33      | 0.70–2.49         | 1.32      | 0.91–1.84 |
| Alcohol intoxication             | 1.72    | 1.28–2.32| 0.62      | 0.33–1.16         | 1.29      | 0.96–1.74 |
| Heroin involvement \(^{bc}\)     | 9785    | 0.06     | 0.03–0.10| 0.75              | 0.33–1.73 | 0.14      | 0.08–0.23 |
| Illicit drug use \(^{bc}\)       | 14 073  | 0.19     | 0.13–0.26| 0.54              | 0.28–1.04 | 0.36      | 0.26–0.50 |
| Non-opioid extramedical pharmaceutical use \(^{bc}\) | 14 073 | 1.63 | 1.27–2.10| 0.67      | 0.42–1.08 | 1.72      | 1.33–2.22 |
| Comorbid mental health symptoms \(^{bc}\) | 14 073 | 1.42 | 1.08–1.86| 0.39      | 0.22–0.70 | 1.23      | 0.94–1.62 |

\(^{a}\) Regression estimates from multinomial logistic regression for each characteristic. \(^{b}\) Significant findings. \(^{c}\) All findings are significant at the 5% level. \(^{d}\) All findings are significant at the 1% level. \(^{e}\) All findings are significant at the 0.1% level. \(^{f}\) All findings are significant at the 0.05% level.
|                                  | Codeine | Fentanyl | Oxycodone | Oxycodone-naloxone |
|----------------------------------|---------|----------|-----------|-------------------|
|                                  | n       | OR       | 95% CI    | OR                | 95% CI | OR  | 95% CI | OR   | 95% CI |
| Comorbid suicidal thoughts or behaviours<sup>b,c</sup> | 14 073  | 4.46     | 3.52–5.66 | 0.22              | 0.12–0.42 | 2.57 | 2.02–3.26 | 2.67 | 1.98–3.61 |
| Comorbid non-suicidal self-injury<sup>b,c</sup>   | 9785    | 2.28     | 0.92–5.65 | 0.70              | 0.13–3.63 | 1.42 | 0.56–3.60 | 1.50 | 0.47–4.78 |
| Accidental overdose<sup>b,c</sup>                 | 14 073  | 0.38     | 0.28–0.52 | 2.89              | 1.97–4.24 | 0.41 | 0.30–0.57 | 0.26 | 0.14–0.47 |
| Unknown intent overdose<sup>b,c</sup>             | 14 073  | 1.43     | 1.07–1.92 | 1.73              | 1.60–2.63 | 1.26 | 0.93–1.69 | 0.62 | 0.40–0.97 |
| Past history of psychiatric issues<sup>b,c</sup>  | 14 073  | 3.18     | 2.58–3.91 | 0.81              | 0.57–1.14 | 1.98 | 1.61–2.44 | 2.36 | 1.79–3.11 |
|                                  | Morphone | Tramadol | Tapentadol | Multiple Opioids  |
|                                  | OR  | 95% CI | OR  | 95% CI | OR  | 95% CI | OR  | 95% CI |
| Glasgow Coma Scale<sup>d</sup> |         |         |         |         |         |         |         |         |
| Non-responsive                   | Ref | Ref   | Ref   | Ref | Ref | Ref | Ref | Ref |
| Severe impairment                | 2.46 | 1.11–5.44 | – | – | 2.15 | 1.07–4.31 |
| Moderate impairment              | 3.67 | 1.91–7.06 | 2.99 | 0.26–34.56 | 1.72 | 0.94–3.15 |
| Minor/no impairment              | 3.96 | 2.41–6.51 | 5.96 | 0.80–44.33 | 2.17 | 1.43–3.31 |
| Age (years)                      |         |         |         |         |         |         |         |         |
| 12–34                            | Ref | Ref   | Ref   | Ref | Ref | Ref | Ref | Ref |
| 35–54                            | 0.48 | 0.37–0.63 | 0.83 | 0.41–1.70 | 0.64 | 0.49–0.84 |
| 55–64                            | 0.28 | 0.19–0.40 | 0.42 | 0.13–1.32 | 0.47 | 0.33–0.67 |
| > 65                             | 0.19 | 0.12–0.30 | 1.09 | 0.43–2.76 | 0.45 | 0.30–0.66 |
| Sex<sup>e</sup>                  |         |         |         |         |         |         |         |         |
| Male                             | Ref | Ref   | Ref   | Ref | Ref | Ref | Ref | Ref |
| Female                           | 1.86 | 1.47–2.33 | 2.30 | 1.26–4.21 | 2.35 | 1.88–2.95 |
| Respiration rate<sup>f</sup>     |         |         |         |         |         |         |         |         |
| < 6                              | Ref | Ref   | Ref | Ref | Ref | Ref | Ref | Ref |
| 6–12                             | 4.35 | 1.90–9.99 | – | – | 2.14 | 1.17–3.91 |
| > 12                             | 7.54 | 3.40–16.74 | – | – | 2.63 | 1.49–4.64 |
| Transport to hospital<sup>b,c</sup> | 1.42 | 1.03–1.96 | 2.82 | 0.85–9.35 | 2.21 | 1.57–3.12 |
| Naloxone administered<sup>b,c</sup> | 0.17 | 0.10–0.27 | 0.12 | 0.02–0.90 | 0.59 | 0.42–0.83 |
| Naloxone response<sup>b,c</sup>  | 0.53 | 0.16–1.84 | – | – | 0.70 | 0.29–1.64 |
| SEIFA quintile<sup>e</sup>       |     |         |         |         |         |         |         |         |
| 1 (greatest disadvantage)        | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref |
## Table 3. (Continued)

| Alcohol involvement | Morphine OR 95% CI | Tramadol OR 95% CI | Tapentadol OR 95% CI | Multiple Opioids OR 95% CI |
|---------------------|-------------------|--------------------|----------------------|--------------------------|
| Alcohol involved, no intoxication | 1.11 (0.74–1.68) | 1.77 (0.72–4.34) | 0.78 (0.30–2.06) | 1.02 (0.68–1.52) |
| Alcohol intoxication | 1.10 (0.79–1.54) | 0.78 (0.30–2.06) | 0.93 (0.67–1.30) | Ref |
| Heroin involvement | 0.14 (0.08–0.28) | 0.05 (0.02–0.13) | Ref |
| Illicit drug use | 0.30 (0.20–0.44) | 0.36 (0.10–1.22) | 0.20 (0.13–0.31) | Ref |
| Non-opioid extramedical pharmaceutical use | 2.30 (1.71–3.09) | 3.66 (1.42–9.44) | 3.14 (2.33–4.22) | Ref |
| Comorbid mental health symptoms | 1.20 (0.88–1.63) | 1.12 (0.50–2.50) | 1.30 (0.96–1.76) | Ref |
| Comorbid suicidal thoughts or behaviours | 2.76 (2.12–3.59) | 3.80 (2.04–7.07) | 3.51 (2.70–4.56) | Ref |
| Comorbid non-suicidal self-injury | 1.86 (0.70–4.97) | 1.60 (0.59–4.32) | Ref |
| Accidental overdose | 0.48 (0.32–0.71) | 0.31 (0.07–1.32) | 0.50 (0.34–0.73) | Ref |
| Unknown intent overdose | 1.26 (0.90–1.75) | 0.31 (0.07–1.30) | 1.35 (0.98–1.87) | Ref |
| Past history of psychiatric issues | 1.95 (1.54–2.48) | 3.35 (1.76–6.39) | 2.40 (1.90–3.04) | Ref |

Bolded text indicates statistically significant differences. *Estimates are using national data unless specified otherwise; reference category is no/not stated/not effective; †adjusted for age group, sex, and concurrent other substance use; ‡adjusted for age group, sex, concurrent alcohol, heroin, illicit drug and other pharmaceutical use; §adjusted for sex and concurrent other substance use; ¶adjusted for age group and concurrent other substance use; insufficient case numbers available for inclusion of state location as effect modifier, estimates produced using Victoria data only; †excluding heroin. OR = odds ratio; CI = confidence interval; SEIFA = Socio-Economic Indexes for Areas.
Victoria appeared representative of the ‘snapshot’ Australian states.

**DISCUSSION**

We examined more than 14,000 ambulance attendances related to extramedical pharmaceutical opioid use to determine if the rates and the severity of attendances differed by opioid type. There are three key findings. First, the rates of attendances differed by opioid, and this was not explained by potency. Different attendance rates were also observed for oxycodone and oxycodone–naloxone. Secondly, the supply-adjusted attendance rates were stable over time, and appeared unaffected by large changes in supply. Thirdly, severity and other attendance characteristics differed by opioid. We now explore these key findings in more detail.

When considering supply-adjusted rates for single-opioid attendances, the highest rate was for codeine (the lowest potency opioid examined), which was more than 50 times that of the lowest rate calculated observed with tapentadol. For buprenorphine (transdermal) and pethidine, attendances were rare (fewer than five each), so rates could not be calculated, although the limited number of cases is a finding in itself. This wide variation in supply-adjusted rates between opioids is contrasted with relative consistency in the supply-adjusted rate over time within individual opioid types, despite considerable changes in some supply volumes over the study period. For example, oxycodone supply volume reduced (~50%) from 2014 to 2018, and oxycodone–naloxone more than doubled during the same period. Tapentadol supply steadily increased from 2013, becoming the fourth most commonly supplied opioid in 2018. This consistency in supply-adjusted rates may suggest that harms relating to specific opioids are more closely linked to the opioids and less affected by context, such as changing patterns of use, greater experience prescribing or knowledge of harms. Low rates of attendees with tapentadol appear consistent with a lower abuse liability reported elsewhere [28,29].

The differences between oxycodone and oxycodone–naloxone attendance rates demonstrate that the opioid alone does not determine the rate of harm. The supply-adjusted rate of oxycodone–naloxone-related attendances was consistently one-third that of oxycodone throughout the study period. The exception to this appears to be in the final 12 months of the observation period, where rates of oxycodone-related harm increased, while supply reduced. Differences in demographic characteristics were also present, with oxycodone-related attendances being more likely to involve younger age groups compared with oxycodone–naloxone-related attendances, although females were over-represented in both groups. For socioeconomic status, for opioids other than fentanyl rates seemed to decrease with disadvantage, and appears broadly consistent with other studies finding that opioid mortality is a concern among all socio-economic groups [30].

The apparent association between availability, formulation and harm is another important consideration. The highest rates of harm were observed with codeine. In Australia, codeine was available in compounded medications without a prescription for the majority of the study period, and as a lesser regulated (Schedule 4) prescription opioid when compounded with acetaminophen or ibuprofen. Sales data indicated that supply was approximately evenly split between the over-the-counter and prescribed codeine, with minimal supply as a restricted single-ingredient product [31]. It is possible that ease of access and the compounded ingredients (e.g. acetaminophen–codeine combinations) contributed to the harms observed. Notably, codeine-related attendances had four times higher odds of having suicidal intent documented and were less likely to represent accidental overdoses. Both codeine and tramadol-related attendances, the two lesser-restricted opioids in Australia, represented largely younger females with suicidal or self-injurious intent, consistent with international evidence [32]. This highlights that not all opioid-related harm can be addressed through measures aimed at accidental overdose.

Finally, although fentanyl-related attendance rates were low, particularly in Victoria, they were characterized by their medical severity, and were reflective of heroin overdoses with low consciousness, respiration, more males, higher rates of naloxone administration and low rates of transport to hospital [33]. This severity of attendances is consistent with other Australian data [34] and considerable opioid-related mortality attributed to the widespread fentanyl supply in North America [35]. In contrast to the cases here, fentanyl is more likely to be prescribed to older adults and to females [36]. In general, there was an over-representation of younger people despite most opioid prescriptions being for older adults [37]. With the exception of morphine and fentanyl-related attendances, both supply data and ambulance data show consistent over-representation of females [37], highlighting the need for female-specific research in this area.

**Implications for policy**

Policy attention has largely focused on accidental overdose, with relatively less focus on intentional harm. Future research may explore the role of regulation to address intentional self-harm. Reduced access to pharmaceuticals may reduce suicide by pharmaceutical self-poisoning, as well as suicide more generally [38,39]. Self-poisoning is a commonly reported modality for suicide attempts [40].
Implications for practice

Most clinical efforts to prevent opioid-related harm have focused on accidental overdose, such as via naloxone distribution programmes, patient education [41] and limiting higher-dose prescribing of opioids for chronic pain [42]. This work is important for stronger opioids (e.g. fentanyl), but may be less relevant to codeine and tramadol-related harms. Understanding the clinical context and contributors to intentional self-harm may inform such initiatives. Prescribers should also be aware of the distinctly different harm profiles with different opioids and opioid formulations, particularly as newer products are introduced.

Strengths and limitations

This paper has a number of strengths. This study is unique, in that it examines a range of harms related to extramedical use, extending existing work that has predominantly focused on overdose as an outcome. This work underscores the need to understand the role of suicide and self-harm in escalating opioid-related mortality [40,43]. As a sensitive and timely population-level indicator of harm, this work highlights the utility of coded ambulance attendances to monitor harms with new opioid formulations, and to evaluate policy changes intended to address opioid-related harm.

There are also limitations with these data. Toxicological results are not available to confirm the reported substances taken, although in many cases documented medical histories confirm patient self-report. The opioid source cannot be determined, thus the contribution of diversion to harm cannot be quantified. These administrative data were not primarily generated for research. The analysis of each attendance by trained coders results in a validated and reliable data set [17], although there are still limitations in the information provided by paramedic clinical notes, which are based on clinical observations, and information provided by patients and others at the scene. Supply-adjusted rates make assumptions around OME, although patterns observed with rates unadjusted for supply appear consistent, suggesting that correcting for underlying volume of supply is unlikely to have biased the result.

Some cases involved multiple opioids, so the contribution of individual opioids cannot be determined in these cases; however, as most cases involved a sole opioid, this lessens the risk that this would have affected our results. This analysis did not explore temporal trends in attendance characteristics, although future analysis to explore trends with oxycodone, where harms appeared to be increasing over time, are warranted. Finally, the low number of tapentadol-related attendances result in relatively wide confidence intervals concerning estimates for demographic characteristics. The lack of differences between tapentadol- and morphine-related attendances may be due to sample size; future studies should revisit these comparisons when more data are available.

In conclusion, this study represents one of the most detailed population-level examinations of pharmaceutical opioid-related harm. We found distinct patterns of rates, types and severity of harms related to different opioids, even when comparing opioids of comparable clinical efficacy. These findings highlight the need to consider factors such as the opioid formulation, and the role of self-harm, to develop nuanced responses to pharmaceutical opioid-related harm.

Declaration of interests

S.N. is the recipient of an NHMRC Career Development Fellowship (1163961). S.N. is a named investigator on research grants from Indivior (unrelated to this work), and has delivered presentations on codeine dependence for Indivior for which her institution received payment. D.L. has received speaking honoraria from the following: AstraZeneca, Camurus AB, Indivior, Janssen-Cilag, Lundbeck, Servier and Shire and has participated on Advisory Boards for Indivior and Lundbeck.

Acknowledgements

This project was funded by an untied educational grant from Seqirus Pty Ltd. The Ambo Project and National Ambulance Surveillance System are funded by the Victorian Department of Health and Human Services, and the Commonwealth Department of Health. Funders had no role in the study design, conduct, analysis or interpretation. We gratefully acknowledge our funders and project partners in the Ambo Project and National Ambulance Surveillance System. This includes the Population Health coding team at Turning Point, led by Sharon Matthews. Our thanks also to the following ambulance service representatives for their valuable support of the National Ambulance Surveillance System: Kevin McLaughlin and Dr Rosemary Carney, Ambulance Service of New South Wales; Alex Wilson, Ambulance Tasmania; Emma Bosley, Queensland Ambulance Service; Michael McKay and Sue-Ellen Skinner, St John Ambulance Northern Territory. We also acknowledge Stephen Wichtowski for his role in designing the search strategy and extraction of tapentadol-related attendances.

References

1. Berterame S., Erthal J., Thomas J., Fellner S., Vosse B., Clare P., et al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet 2016; 387: 1644–56.
2. Scholl L., Seth P., Kariisa M., Wilson N., Baldwin G. Drug and opioid-involved overdose deaths—United States, 2013–2017. Morb Mortal Wkly Rep 2018; 67: 1419–27.
3. Rexburgh A., Dobbins T., Degenhardt L., Peacock A. Opioid-, Amphetamine-, and Cocaine-Induced Deaths in Australia: August 2018. Sydney: National Drug and Alcohol Research Centre; 2018; p. 2018.

4. Rexburgh A., Hull W. D., Dobbins T., Gisev N., Burns L., Pearson S., et al. Trends in heroin and pharmaceutical opioid overdose deaths in Australia. Drug Alcohol Depend 2017; 179: 192–8.

5. Drewes A. M., Jensen R. D., Nielsen L. M., Droney J., Christrup L. L., Arendt-Nielsen L., et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol 2013; 75: 60–78.

6. Murphy D. L., Lebin J. A., Severtson S. G., Olson H. A., Dasgupta N., Dart R. C. Comparative rates of mortality and serious adverse effects among commonly prescribed opioid analogs. Drug Saf 2018; 41: 787–95.

7. Ordonez Gallego A., Gonzalez Baron M., Espinosa A. E. Oxycodeone: a pharmacological and clinical review. Clin Transl Oncol 2007; 9: 298–307.

8. Conner S. D., Cuijil C. M. Fentanyl: receptor pharmacology, abuse potential, and implications for treatment. Neurosci Biobehav Rev 2019; 106: 49–57.

9. Miotto K., Cho A. K., Khalil M. A., Blanco K., Susuki J. D., Rawson R. Trends in tramadol: pharmacology, metabolism, and misuse. Anesth Analgy 2017; 124: 44–51.

10. Bravo L., Mico J. A., Berrocoso E. Discovery and development of tramadol for the treatment of pain. Expert Opin Drug Discov 2017; 12: 1281–91.

11. Vadiwela N., Timchenko A., Huang Y., Sinatra R. Tapentadol extended-release for treatment of chronic pain: a review. J Pain Res 2011; 4: 211–8.

12. Wightman R., Perrone J., Portelli I., Nelson L. Likeability and abuse liability of commonly prescribed opioids. J Med Toxicol 2012; 8: 335–40.

13. Babalonis S., Lofwall M. R., Nuzzo P. A., Siegel A. J., Walsh S. L. Abuse liability and reinforcing efficacy of oral tramadol in humans. Drug Alcohol Depend 2013; 129: 116–24.

14. Cicero T. J., Ellis M. S., Suratt H. L., Kurtz S. P. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry 2014; 71: 821–6.

15. Peacock A., Gibbs D., Sutherland R., Uporova J., Karlsson A., Bruno R., et al. Canadian Drug Trends 2018: Key Findings from the National Illicit Drug Reporting System (IDRS) Interviews, Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2018.

16. Palleria C., Leporini C., Chimirri S., Marrazzo G., Sacchetta S., Bruno L., et al. Limitations and obstacles of the spontaneous adverse drug reactions reporting: two ‘challenging’ case reports. J Pharmacol Pharmacother 2013; 4: S66–872.

17. Nielsen S., Crossin R., Middleton M., Martin C., Wilson J., Lam S., et al. Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Australia: a protocol for a retrospective observational study. BMJ Open 2019; 9: e029170.

18. Australian Bureau of Statistics. 3101.0—Australian Demographic Statistics, 2018. Available at: http://www.abs.gov.au/ausstats/abs@.nsf/mf/3101.0.

19. Crossin R., Scott D., Arunogiri S., Smith K., Dietze P. M., Lubman D. I. Pregabalin misuse-related ambulance attendances in Victoria, 2012–2017: characteristics of patients and attendances. Med J Aust 2019; 210: 75–9.

20. Hellbronn C., Lloyd B., McElwee P., Eade A., Lubman D. I. Trends in quetiapine use and non-fatal quetiapine-related ambulance attendances. Drug Alcohol Rev 2013; 32: 405–11.

21. Turning Point. Ambo-AODStats 2018. Available at: http://amboaodstats.org.au/ (accessed date October 12, 2018).

22. Rhodes A. E., Bethell J., Spence J., Links P. S., Steiner D. L., Jaukkaisetan R. L. Age-sex differences in medicinal self-poisonings: a population-based study of deliberate intent and medical severity. Soc Psychiatry Psychiatr Epidemiol 2008; 43: 642–52.

23. Gunnell D., Ho D., Murray V. Medical management of deliberate drug overdose: a neglected area for suicide prevention? Emerg Med J 2004; 21: 35–8.

24. Nielsen S., Degenhardt L., Hoban B., Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoeconomics Drug Saf 2016; 25: 733–7.

25. Nielsen S., Gisev N., Bruno R., Hall W., Cohen M., Larance B., et al. Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. Pharmacoeconomics Drug Saf 2017; 26: 587–91.

26. Australian Bureau of Statistics. 2033.0.55.001—Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia, 2016. Canberra: Australian Bureau of Statistics; 2018.

27. Fiese R. J. Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol 2002; 2: 8.

28. Vosburg S. K., Severtson S. G., Dart R. C., Cicero T. J., Kurtz S. P., Parrino M. W., et al. Assessment of Tapentadol API abuse liability with the researched abuse, diversion and addiction-related surveillance system. J Pain 2018; 19: 439–53.

29. Butler S. F., McNaughton E. C., Black R. A. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment. Pain Med 2015; 16: 119–30.

30. Shiel M. S., Berrington de Gonzalez A., Best A. E., Chen Y., Chernyavskyi P., Hartge P., et al. Premature mortality from all causes and drug poisonings in the USA according to socioeconomic status and rurality: an analysis of death certificate data by county from 2000–15. Lancet Public Health 2019; 4: e97–e106.

31. Gisev N., Nielsen S., Cama E., Larance B., Bruno R., Degenhardt L. An ecological study of the extent and factors associated with the use of prescription and over-the-counter codeine in Australia, Eur J Clin Pharmacol 2016; 72: 469–94.

32. Halkin M., Launuieni T., Vuori E., Ojanpera I. Comparison of fatal poisonings by prescription opioids. Forensic Sci Int 2012; 222: 327–31.

33. Dietze P., Jolley D., Cvetkovski S., Cantwell K., Jauncey M., Salmon A. M. Characteristics of non-fatal opioid overdoses attended by ambulance services in Australia. Aust NZ J Public Health 2004; 28: 569–75.

34. Latimer J., Ling S., Flaherty I., Jauncey M., Salmon A. M. Risk of fentanyl overdose among clients of the Sydney medically supervised injecting Centre. Int J Drug Policy 2016; 37: 113–4.

35. Seth P., Scholl L., Rudd R. A., Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. Morb Mortal Wkly Rep 2018; 67: 349–58.

36. Gisev N., Pearson S. A., Larance B., Larney S., Blanch L., Degenhardt L. A population-based study of transdermal fentanyl initiation in Australian clinical practice. Eur J Clin Pharmacol 2019; 75: 401–8.
Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.